Patents by Inventor Beth Borowsky
Beth Borowsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075021Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.Type: ApplicationFiled: October 19, 2023Publication date: March 7, 2024Applicant: Prilenia Neurotherapeutics Ltd.Inventors: Michael HAYDEN, Spyridon PAPAPETROPOULOS, Juha-Matti SAVOLA, Eli EYAL, Beth BOROWSKY, Igor D. GRACHEV, Mark Forrest GORDON
-
Patent number: 11826361Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.Type: GrantFiled: February 24, 2019Date of Patent: November 28, 2023Assignee: PRILENIA NEUROTHERAPEUTICS LTDInventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor D. Grachev, Mark Forrest Gordon
-
Patent number: 11207310Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.Type: GrantFiled: August 24, 2017Date of Patent: December 28, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor Grachev
-
Publication number: 20190192496Abstract: The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.Type: ApplicationFiled: February 24, 2019Publication date: June 27, 2019Applicant: PRILENIA THERAPEUTICS DEVELOPMENT LTD.Inventors: Michael HAYDEN, Spyridon PAPAPETROPOULOS, Juha-Matti SAVOLA, Eli EYAL, Beth BOROWSKY, Igor D. GRACHEV, Mark Forrest GORDON
-
Publication number: 20180055832Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.Type: ApplicationFiled: August 24, 2017Publication date: March 1, 2018Applicant: Teva Pharmaceuticals International GmbHInventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor D Grachev
-
Publication number: 20080221078Abstract: The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CB1 receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders. The combination of this invention provides synergistic results in that the combination improves positive and negative symptoms of schizophrenia, weight gain and catalepsy.Type: ApplicationFiled: May 22, 2008Publication date: September 11, 2008Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Mark BLACK, Beth BOROWSKY, Nancy ROGACKI, Yaw SENYAH, Rachel STEVENS
-
Publication number: 20070129403Abstract: The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula I wherein in is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, hydroxy, nitro or amino; each R1 is independently hydrogen, C1-C6alkyl, C1-C6alkenyl, C1-C6alkanoyl, halogen, cyano, —C(O)C1-C6alkyl, —C1-C6alkyleneCN, —C1-C6alkyleneNR?R? wherein R? and R? are each independently hydrogen or C1-C6alkyl, —C1-C6alkyleneOC(O)C1-C6alkyl, or —CH(OH)R4 wherein R4 is hydrogen or C1-C6alkyl; R2 is hydrogen, C1-C6alkyl optionally substituted with halogen, hydroxy or benlzyloxy, C1-C6alkenyl, C1-C6alkynyl, —CO2C1-C6alkyl, or —R5—NR?R? wherein R5 is C1-C6alkylene, C1-C6alkenylene or C1-C6alkynylene and R? and R? are each independently hydrogen, C1-C6alkyl or alternatively the group —NR?R? as a wholeType: ApplicationFiled: September 29, 2006Publication date: June 7, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Craig Smith, David Rampe, Beth Borowsky, Sathapana Kongsamut
-
Publication number: 20070028315Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF33 receptors, purified mammalian SNORF33 receptors, vectors comprising nucleic acid encoding mammalian SNORF33 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF33 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF33 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF33 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF33 receptors, methods of isolating mammalian SNORF33 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF33 receptors, as well as methods of determining binding of compounds to mammalian SNORF33 receptors, methods of identifying agonists and antagonists of SNORF33 receptors, and agonists and antagonists so identified.Type: ApplicationFiled: September 15, 2005Publication date: February 1, 2007Inventors: Beth Borowsky, Kristine Ogozalek, Kenneth Jones
-
Patent number: 7041461Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.Type: GrantFiled: May 25, 2001Date of Patent: May 9, 2006Assignee: H. Lundbeck A/SInventors: Christophe P. G. Gerald, Kenneth A. Jones, James A. Bonini, Beth Borowsky
-
Publication number: 20060074233Abstract: This invention provides isolated nucleic acids encoding mammalian SNORF33 receptors, purified mammalian SNORF33 receptors, vectors comprising nucleic acid encoding mammalian SNORF33 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF33 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF33 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF33 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF33 receptors, methods of isolating mammalian SNORF33 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF33 receptors, as well as methods of determining binding of compounds to mammalian SNORF33 receptors, methods of identifying agonists and antagonists of SNORF33 receptors, and agonists and antagonists so identified.Type: ApplicationFiled: September 1, 2005Publication date: April 6, 2006Inventors: Beth Borowsky, Kristine Ogozalek, Kenneth Jones
-
Patent number: 7022489Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: GrantFiled: December 3, 2001Date of Patent: April 4, 2006Assignee: H. Lundbeck A/SInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P. G. Gerald, Kenneth A. Jones
-
Publication number: 20050260687Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.Type: ApplicationFiled: November 18, 2004Publication date: November 24, 2005Inventors: Christophe Gerald, Kenneth Jones, James Bonini, Beth Borowsky, Douglas Craig
-
Publication number: 20050089937Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.Type: ApplicationFiled: November 18, 2004Publication date: April 28, 2005Inventors: Christophe Gerald, Kenneth Jones, James Bonini, Beth Borowsky, Douglas Craig
-
Patent number: 6770444Abstract: This invention provides an isolated nucleic acid encoding a polypeptide, a purified polypeptide, vectors comprising isolated nucleic acid encoding a polypeptide, cells comprising such vectors, antibodies directed to a polypeptide, nucleic acid probes useful for detecting nucleic acid encoding a polypeptide, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a polypeptide, nonhuman transgenic animals which express DNA encoding a normal or a mutant polypeptide, methods of isolating a polypeptide, methods of treatment eating disorders as well as methods of determining binding of compounds to polypeptides.Type: GrantFiled: July 16, 1998Date of Patent: August 3, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Nika Adham, Beth Borowsky, Nigel Levens, Radek Ctirad Skoda
-
Publication number: 20030119096Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: December 3, 2001Publication date: June 26, 2003Inventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith
-
Publication number: 20030082641Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: January 26, 2001Publication date: May 1, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
-
Publication number: 20030082623Abstract: This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors.Type: ApplicationFiled: July 5, 2001Publication date: May 1, 2003Inventors: Beth Borowsky, Thomas P. Blackburn, Kristine Ogozalek
-
Publication number: 20030073829Abstract: This invention provides an isolated nucleic acid encoding a polypeptide, a purified polypeptide, vectors comprising isolated nucleic acid encoding a polypeptide, cells comprising such vectors, antibodies directed to a polypeptide, nucleic acid probes useful for detecting nucleic acid encoding a polypeptide, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a polypeptide, nonhuman transgenic animals which express DNA encoding a normal or a mutant polypeptide, methods of isolating a polypeptide, methods of treatment eating disorders as well as methods of determining binding of compounds to polypeptides.Type: ApplicationFiled: July 16, 1998Publication date: April 17, 2003Inventors: NIKA ADHAM, BETH BOROWSKY, NIGEL LEVENS, RADEK C. SKODA
-
Publication number: 20030027254Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.Type: ApplicationFiled: December 3, 2001Publication date: February 6, 2003Applicant: Synaptic Pharmaceutical CorporationInventors: Jonathan A. Bard, Beth Borowsky, Kelli E. Smith, Theresa A. Branchek, Christophe P.G. Gerald, Kenneth A. Jones
-
Publication number: 20020198367Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.Type: ApplicationFiled: May 25, 2001Publication date: December 26, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Christophe P.G. Gerald, Kenneth A. Jones, James A. Bonini, Beth Borowsky